FAQ on Kairos Pharma Ltd.'s DoD Grant for Lung Cancer Biomarker Research

What is the purpose of the DoD grant awarded to Kairos Pharma Ltd.?

The $876,000 grant from the U.S. Department of Defense is to support biomarker research for Kairos’ Phase 1 trial of ENV105 in EGFR-driven non-small cell lung cancer, focusing on patients developing resistance to osimertinib.

Why is this research significant?

This research is significant because it aims to identify patients who may benefit from early intervention with ENV105, potentially improving long-term outcomes through targeted therapy and precision monitoring in non-small cell lung cancer.

How does ENV105 work in treating cancer?

ENV105 is an antibody that targets CD105, a protein identified as a key driver of resistance to various cancer treatments, aiming to reverse drug resistance and restore the effectiveness of standard therapies across multiple cancer types.

Who is conducting the research supported by the DoD grant?

The research is being conducted at Cedars-Sinai Medical Center, specifically in Dr. Neil Bhowmick’s lab, as part of Kairos Pharma Ltd.’s strategy to advance cancer treatment.

Where can I find more information about Kairos Pharma Ltd.?

More information about Kairos Pharma Ltd. can be found on their website at www.KairosPharma.com or in the company’s newsroom at https://ibn.fm/KAPA.

What are the current clinical trials involving ENV105?

ENV105 is currently in a Phase 2 clinical trial for castrate resistant prostate cancer and a Phase 1 trial for lung cancer, addressing significant unmet medical needs in these areas.

What is the focus of the Phase 1 trial of ENV105?

The Phase 1 trial of ENV105 focuses on EGFR-driven non-small cell lung cancer, specifically on patients developing resistance to osimertinib, to identify those who may benefit from early intervention with ENV105.